Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.
Checked against the public recordLast updated Oct 28, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: Erlotinib; Drug: Erlotinib; Drug: PF-02341066
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * histologically proven diagnosis of Non-Small Cell Lung Cancer (NSCLC) that is locally advanced or metastatic and of the adenocarcinoma subtype (including mixed adenosquamous histology) * evident disease progression by Response Evaluation Criterion in Solid Tumors (RECIST) after at least one but no more than 2 chemotherapy regimens for advanced disease * tumors must have measurable disease as per RECIST Exclusion Criteria: * known interstitial lung disease * prior treatment with an agent that is known or proposed to be active by action on EGFR tyrosine kinase or c-Met/HGF (Phase 2 Portion)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Alabama at BirminghamBirmingham, Alabama
- University of Alabama at BirminghamBirmingham, Alabama
- University of California, Irvine Medical Center PharmacyOrange, California
- University of California, Irving - Medical CenterOrange, California
- University of California IrvinOrange, California
- Holy Cross HospitalFort Lauderdale, Florida
- Siteman Cancer CenterCity of Saint Peters, Missouri
- Siteman Cancer Center -West CountyCreve Coeur, Missouri
- Barnes-Jewish HospitalSt Louis, Missouri
- Washington University, School of MedicineSt Louis, Missouri
- OSU EastColumbus, Ohio
- The Ohio State University James Cancer HospitalColumbus, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 28, 2015. Always confirm current availability with the study team.